Asset Details
Do you wish to reserve the book?
Efficacy and safety of emulsified microsomal ferric pyrophosphate vs. Ferrous Ascorbate in pregnancy with iron-deficiency anemia- a randomized, comparative study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and safety of emulsified microsomal ferric pyrophosphate vs. Ferrous Ascorbate in pregnancy with iron-deficiency anemia- a randomized, comparative study
Do you wish to request the book?
Efficacy and safety of emulsified microsomal ferric pyrophosphate vs. Ferrous Ascorbate in pregnancy with iron-deficiency anemia- a randomized, comparative study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and safety of emulsified microsomal ferric pyrophosphate vs. Ferrous Ascorbate in pregnancy with iron-deficiency anemia- a randomized, comparative study
2025
Overview
This study evaluates the efficacy and safety of emulsified microsomal Ferric pyrophosphate (EMFP/SunActive™ Fe, 27 mg elemental iron) versus Ferrous Ascorbate (100 mg elemental iron) in second-trimester pregnant women with iron-deficiency anemia (IDA) for 4 weeks. Pregnant women aged 20–35 years with a singleton pregnancy, hemoglobin (Hb) 9–10.5 g/dL, and ferritin < 15 mcg/L were enrolled. The test group showed zero adverse effects vs. the control group, having 11.1% adverse events. The gastrointestinal(GI) adverse symptoms, including nausea, dark stools, and hyperacidity, were reported only in the Ferrous Ascorbate group, indicating superior tolerability and safety of EMFP tablets. Both groups showed similar improvements in Hb (Δ2.63 g/dL vs. Δ2.62 g/dL) and serum ferritin (61.09% vs. 61.92%). Reticulocyte hemoglobin (RET-He) increased by 20.5% in the test group and 16.2% in the control group, with no significant difference. Clinical symptoms such as dizziness, fatigue, and palpitations improved with greater magnitude in the test group. It was inferred that the test group receiving EMFP was as effective as the control group in improving efficacy endpoints at a significantly lower dose (1/3rd dose compared to ascorbate). EMFP showed better tolerability, safety and compliance, making it a promising option for managing IDA in pregnant women.
Publisher
Nature Publishing Group,Nature Portfolio
Subject
/ Anemia
/ Anemia, Iron-Deficiency - blood
/ Anemia, Iron-Deficiency - drug therapy
/ Ascorbic Acid - administration & dosage
/ Ascorbic Acid - adverse effects
/ Ascorbic Acid - therapeutic use
/ Consent
/ Diphosphates - administration & dosage
/ Diphosphates - adverse effects
/ Diphosphates - therapeutic use
/ Emulsified ferric pyrophosphate
/ Ethics
/ Female
/ Ferritin
/ Ferrous Compounds - administration & dosage
/ Ferrous Compounds - adverse effects
/ Ferrous Compounds - therapeutic use
/ Humans
/ Iron
/ M cells
/ Patients
/ Pregnancy Complications, Hematologic - blood
/ Pregnancy Complications, Hematologic - drug therapy
/ Safety
